ArticlePloS one2012
Stenotrophomonas maltophilia infections in a general hospital: patient characteristics, antimicrobial susceptibility, and treatment outcome.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The prevalence of colistin resistance in clinical Stenotrophomonas maltophilia isolates worldwide: a systematic review and meta-analysis.BMC microbiology · 2023Pooled it
- Global prevalence and antibiotic resistance in clinical isolates ofFrontiers in medicine · 2023Pooled it
- Treatment Patterns and Clinical Outcomes in Children withMicroorganisms · 2026Article
- Clinical, microbiological, and molecular characteristics, outcomes, and risk factors for mortality of patients with Stenotrophomonas maltophilia bloodstream infection.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- A polyvalent phage shapes bacterial dynamics.Journal of virology · 2026Article
- Temporal trends, antimicrobial non-susceptibility patterns, and clinical predictors of Stenotrophomonas maltophilia in a tertiary care hospital in Palestine: a 7-year retrospective study.BMC infectious diseases · 2026Observational
- What Drives Mortality inMicroorganisms · 2025Article
- In vitro antimicrobial activity and clinical use of trimethoprim-sulfamethoxazole for infections due to KPC-producing Gram-negative pathogens: a review.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Review
- Deciphering Bacterial Community Succession and Pathogen Dynamics in ICU Ventilator Circuits Through Full-Length 16S rRNA Sequencing for Mitigating the Risk of Nosocomial Infections.Microorganisms · 2025Article
- Investigation and Management of a Small Outbreak of Septic Knee Arthritis Following Knee Arthroscopy byJournal of medical cases · 2025Article
- Cefiderocol for the Treatment of Nosocomial Bloodstream Infections Caused by Stenotrophomonas maltophilia: A Case Series and Literature Review.Infectious diseases and therapy · 2025Article
- Does Antibiotic Use Contribute to Biofilm Resistance in Sink Drains? A Case Study from Four German Hospital Wards.Antibiotics (Basel, Switzerland) · 2024Article
- Characterization of phage evolution and phage resistance in drug-resistantJournal of virology · 2024Article
- Carriage of multiple resistance genes by community and hospital isolates ofThe Pan African medical journal · 2024Article
- Antibiotic Resistance and Virulence Factors in Clinical Isolates ofInternational journal of microbiology · 2024Article
- UpraisingDiagnostics (Basel, Switzerland) · 2023Article
- Genotypic Diversity, Antibiotic Resistance, and Virulence Phenotypes ofAntibiotics (Basel, Switzerland) · 2023Article
- Characterization of Antibiotic-Resistant Stenotrophomonas Isolates from Painted Turtles Living in the Wild.Current microbiology · 2023Article
- Pulmonary bacteriophage and cystic fibrosis airway mucus: friends or foes?Frontiers in medicine · 2023Review
- Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionStenotrophomonas maltophilia is acquiring increasing importance as a nosocomial pathogen.
methodsWe retrospectively studied the characteristics and outcome of patients with any type of S. maltophilia infection at the University Hospital of Heraklion, Crete, Greece, between 1/2005-12/2010. S. maltophilia antimicrobial susceptibility was tested with the agar dilution method. Prognostic factors for all-cause in-hospital mortality were assessed with multivariate logistic regression.
resultsSixty-eight patients (median age: 70.5 years; 64.7% males) with S. maltophilia infection, not related to cystic fibrosis, were included. The 68 patients were hospitalized in medical (29.4%), surgical (26.5%), hematology/oncology departments (23.5%), or the intensive care units (ICU; 20.6%). The most frequent infection types were respiratory tract (54.4%), bloodstream (16.2%), skin/soft tissue (10.3%), and intra-abdominal (8.8%) infection. The S. maltophilia-associated infection was polymicrobial in 33.8% of the cases. In vitro susceptibility was higher to colistin (91.2%), trimethoprim/sulfamethoxazole and netilmicin (85.3% each), and ciprofloxacin (82.4%). The empirical and the targeted treatment regimens were microbiologically appropriate for 47.3% and 63.6% of the 55 patients with data available, respectively. Most patients received targeted therapy with a combination of agents other than trimethoprim/sulfamethoxazole. The crude mortality and the mortality and the S. maltophilia infection-related mortality were 14.7% and 4.4%, respectively. ICU hospitalization was the only independent prognostic factor for mortality.
conclusionS. maltophilia infection in a general hospital can be associated with a good prognosis, except for the patients hospitalized in the ICU. Combination reigmens with fluoroquinolones, colistin, or tigecycline could be alternative treatment options to trimethoprim/sulfamethoxazole.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.